



U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)										Atty. Docket No. 62942-B/JPW/AJD		Serial No. 09/912,824			
										Applicant(s) Graham P. Allaway et al.					
										Filing Date July 25, 2001				Group Art Unit 1648	
U.S. PATENT DOCUMENTS															
Examiner Initials	Exh. No. [§]	Document Number							Date	Name	Class	Subclass	Filing Date If Appropriate		
	1	5	4	6	4	9	6	3	11/07/95	Bolognesi et al.					
	2	5	6	0	3	9	3	3	02/18/97	Dwyer et al.					
	3	5	6	6	8	1	4	9	09/16/97	Oroszlan et al.					
	4	5	8	1	7	7	6	7	10/06/98	Allaway et al.					
FOREIGN PATENT DOCUMENTS															
		Document Number							Date	Country	Class	Subclass	Translation		
														Yes	No
	42	9	2	0	1	4	5	1	02/06/92	PCT					
	43	9	6	4	1	0	2	0	12/19/96	PCT					
	44	9	7	2	6	0	0	9	07/24/97	PCT					
	45	9	7	3	7	0	0	5	10/27/97	PCT					
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)															
	58	Allaway, G.P. et al. (1995) Expression and characterization of CD4-IgG2, a novel heterotetramer which neutralizes primary HIV-1 isolates. AIDS Res. Hum. Retroviruses 11: 533-539;													
	59	Allaway, G.P. et al. (1993) Synergistic inhibition of HIV-1 envelope-mediated cell fusion by CD4-based molecules in combination with antibodies to gp120 or gp41. AIDS Res. Hum. Retroviruses 9: 581-587;													
	60	Allaway, G.P. et al. (1993) Synergistic inhibition of HIV-1 envelope-mediated cell fusion by CD4-based molecules in combination with antibodies to gp120 or gp41. J. Cell. Biochem. 17E: 25, see abstract;													
	61	Amara, A. et al. (1997) HIV coreceptor downregulation as antiviral principle: SDF-la-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication. J. Exp. Med. 186: 139-146;													
	62	Arthos, J. et al. (1989) Identification of the residues in human CD4 critical for the binding of HIV. Cell 57: 469-481;													
	63	Berger, E.A. 1997. HIV entry and tropism: the chemokine receptor connection. AIDS 11 (suppl A): S3-S16;													
	64	Bieniasz, P.D. et al. (1997) HIV-1 induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR5 co-receptor. EMBO J. 16: 2599-2609;													
EXAMINER										DATE CONSIDERED					
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.															

[§] Note that this column shows Exhibit numbers, not reference numbers. Reference numbers are listed on pages 14-31 of the attached Amendment.

10/25/2004 RFEKADU1 00000144 09912824

04 FC:1806

180.00 OP

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)										Graham P. Allaway et al. Filing Date July 25, 2001		Group Art Unit 1648			
U.S. PATENT DOCUMENTS															
Examiner Initials	Exh. No. [§]	Document Number							Date	Name	Class	Subclass	Filing Date If Appropriate		
	5	5	9	9	4	5	1	5	11/30/99	Hoxie					
	6	6	5	2	8	6	2	5	03/04/03	Wu et al.					
	7	6	5	4	8	6	3	6	04/15/03	Dragic et al.					
	8	6	6	9	2	7	4	5	02/17/04	Olson et al.					
	9	6	7	5	9	5	1	9	07/06/04	Li et al.					
	10	Pending claims in 09/888,938								Allaway et al.				06/25/01	
FOREIGN PATENT DOCUMENTS															
		Document Number							Date	Country	Class	Subclass	Translation		
														Yes	No
	46	9	7	4	5	5	4	3	12/04/97	PCT					
	47	9	7	4	7	3	1	9	12/18/97	PCT					
	48	9	7	4	9	4	2	4	12/31/97	PCT					
	49	9	8	1	8	8	2	6	05/07/98	PCT					
	50	9	8	5	6	4	2	1	12/17/98	PCT					
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)															
65	Brelot, A. et al. (1997) Role of the first and third extracellular domains of CXCR4 in human immunodeficiency virus coreceptor activity. J. Virol. 71: 4744-4751;														
66	Burkly, L. et al. (1995) Synergistic inhibition of human immunodeficiency virus type 1 envelope glycoprotein-mediated cell fusion and infection by an antibody to CD4 domain 2 in combination with anti-gp120 antibodies. J. Virol. 69: 4267-4273;														
67	Burton, D.R. et al. (1994) Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266: 1024-1027;														
68	Capon, D.J. et al. (1989) Designing CD4 immunoadhesins for AIDS therapy. Nature 337: 525-531;														
69	Chan, D.C. et al. (1998) Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc. Natl. Acad. Sci. U.S.A. 95: 15613-15617;														
70	Chan, D.C. et al. (1998) HIV entry and its inhibition. Cell 93: 681-684;														
EXAMINER									DATE CONSIDERED						
									01/22/05						
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.															

§ Note that this column shows Exhibit numbers, not reference numbers. Reference numbers are listed on pages 14-31 of the attached Amendment.



Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
62942-B/JPW/AJDSerial No.
09/912,824Applicant(s)
Graham P. Allaway et al.Filing Date
July 25, 2001Group Art Unit
1648INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

Examiner Initials	Exh. No. [§]	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
Y	11	Allowed claims in 10/323,314		Dragic et al.			12/19/02
	12	0 8 6 2 7 6 8 4		Allaway et al.			04/02/96
		60 0 1 4 5 3 2		Allaway et al.			04/02/96
	13	0 8 6 6 3 6 1 6		Allaway et al.			06/14/96
		60 0 1 9 7 1 5		Allaway et al.			06/14/96
	14	0 8 6 7 3 6 8 2		Allaway et al.			06/25/96
	15	0 8 6 6 5 0 9 0		Allaway et al.			06/14/96

FOREIGN PATENT DOCUMENTS

	Exh. No.	Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
Y	51	0 0 3 5 4 0 9	06/22/00	PCT				
	52	0 1 5 5 4 3 9	08/02/01	PCT				
	53	0 1 6 4 7 1 0	09/07/01	PCT				
	54	0 2 2 2 0 7 7	03/21/02	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Y	71	Chen, Z. et al. (1997) Genetically divergent strains of simian immunodeficiency virus use CCR5 as a coreceptor for entry. J. Virol. 71: 2705-2714;
	72	Choe, H. et al. (1996) The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85: 1135-1148;
	73	Clapham, P.R. et al. (1989) Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells. Nature 337: 368-370;
	74	Co, M.S. et al. (1991) Humanized antibodies for antiviral therapy. Proc. Natl. Acad. Sci. U.S.A. 88: 2869-2873;
	75	Connor, R.I. et al. (1997) Change in co-receptor use correlates with disease progression in HIV-1 infected individuals. J. Exp. Med. 185: 621-628;
	76	Crump, M.P. et al. (1997) Solution structure and basis for functional activity of stromal-cell derived factor-1; disassociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO J. 16: 6996-7007;

EXAMINER

DATE CONSIDERED

01/22/05

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[§] Note that this column shows Exhibit numbers, not reference numbers. Reference numbers are listed on pages 14-31 of the attached Amendment.



PTO-1449

**U.S. Department of Commerce
Patent and Trademark Office**

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Atty. Docket No.
62942-B/JPW/AJD

Serial No.
09/912,824

Applicant(s)
Graham P. Allaway et al.

Filing Date
July 25, 2001

Group Art Unit
1648

U.S. PATENT DOCUMENTS

Examiner Initials	Exh. No. [§]	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
		60 0 1 9 9 4 1		Allaway et al.			06/14/96
	16	0 8 8 7 4 5 7 0		Allaway et al.			06/13/97
	17	0 8 8 7 4 6 1 8		Allaway et al.			06/13/97
	18	Pending claims in 09/724,105		Allaway et al.			11/28/00
	19	Pending claims in 09/852,238		Allaway et al.			05/09/01
		0 9 2 1 2 7 9 3		Olson et al.			12/16/98
		60 1 1 2 5 3 2		Olson et al.			12/16/98

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	55	0 2 0 6 8 6 0 8	09/06/02	PCT				
	56	0 2 0 8 3 1 7 2	10/24/02	PCT				
	57	0 3 0 7 2 7 6 6	09/04/03	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	77	Cushman, M. et al. (1991) Preparation and anti-HIV activities of aurintricarboxylic acid fractions and analogues: direct correlation of antiviral potency with molecular weight. J. Med. Chem. 34: 329-337;
	78	Dalgleish, A.G. et al. (1984) The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312: 763-766;
	79	Deen, K.C. et al. (1988) A soluble form of CD4 (T4) protein inhibits AIDS virus infection. Nature 331: 82-84;
	80	Deng, H. et al. (1996) Identification of a major co-receptor for primary isolates of HIV-1. Nature 381: 661-666
	81	De Rossi, A. et al. (1995) Synthetic peptides from the principle neutralizing domain of human immunodeficiency virus type 1 (HIV-1) enhance HIV-1 infection through a CD4-dependent mechanism. Virology 184: 187-196

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[§] Note that this column shows Exhibit numbers, not reference numbers. Reference numbers are listed on pages 14-31 of the attached Amendment.

Patent and Trademark Office INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicant(s) Graham P. Allaway et al.		Filing Date July 25, 2001		Group Art Unit 1648	
U.S. PATENT DOCUMENTS										
Examiner Initials	Exh. No. [§]	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate			
	20	0 9 4 6 4 9 0 2		Olson et al.			12/16/99			
	21	0 9 5 9 4 9 8 3		Olson et al.			06/15/00			
	22	0 9 6 6 3 2 1 9		Olson et al.			09/15/00			
	23	60 2 8 2 3 8 0		Olson et al.			04/06/01			
	24	60 2 6 6 7 3 8		Olson et al.			02/06/01			
	25	2 0 0 2 / 0 1 4 6 4 1 5	10/10/02	Olson et al.						
	26	10 0 8 1 1 2 8		Olson et al.			02/22/02			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)										
	82	Donzella, G.A. et al. (1998) AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat. Med. 4: 72-77;								
	83	Doranz, B.J. et al. (1997) A small molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 co-receptor. J. Exp. Med. 186: 1395-1400;								
	84	Doranz, B.J. et al. (1996) A dual-tropic primary HIV-1 isolate that uses fusin and beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85: 1149-1158;								
	85	Doranz, B.J. et al. (1997) Two distinct CCR5 domains can mediate co-receptor usage by human immunodeficiency virus type 1. J. Virol. 71: 6305-6314;								
	86	Dragic, T. et al. (1996) HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381: 667-673;								
	87	Eckert, D.M. et al. (1999) Inhibiting HIV-1 entry: Discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 99: 103-115;								
	88	Feng, Y. et al. (1996) HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272: 872-877;								
	89	Ferrer, M. et al. (1999) Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements. Nature Struct. Biol. 6: 953-959;								
	90	Fouts, T.R. et al. (1997) Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. J. Virol. 71: 2779-2785;								
	91	Fradd, F. et al. (1989) AIDS Vaccines: An Investor's Guide by Shearman Lehman Hutton. Page 10 (Fig. 2);								
EXAMINER					DATE CONSIDERED					
					01/22/05					
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609 [§] . Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.										

[§] Note that this column shows Exhibit numbers, not reference numbers. Reference numbers are listed on pages 14-31 of the attached Amendment.

Patent and Trademark Office INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicant(s) Graham P. Allaway et al.			
					Filing Date July 25, 2001		Group Art Unit 1648	
U.S. PATENT DOCUMENTS								
Examiner Initials	Exh. No. [§]	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate	
		60 3 5 8 8 8 6		Olson et al.			02/22/02	
	27	2 0 0 3 / 0 0 4 4 4 1 1	03/06/03	Olson et al.				
	28	2 0 0 3 / 0 0 9 2 6 3 2	05/15/03	Dragic et al.				
	29	2 0 0 3 / 0 2 2 8 3 0 6	12/11/03	Olson et al.				
	30	Pending claims in 10/763,545		Olson et al.			01/23/04	
	31	Pending claims in 09/460,216		Allaway et al.			12/13/99	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
	92	Gait, M.J. et al. (1995) Progress in anti-HIV structure-based drug design. Trends Biotech. 13: 430-437;						
	93	Gauduin, M.C. et al. (1996) Effective ex vivo neutralization of plasma HIV-1 by recombinant immunoglobulin molecules. J. Virol. 70: 2586-2592;						
	94	Hill, C.M. et al. (1998) The amino terminus of human CCR5 is required for its function as a receptor for diverse human and simian immunodeficiency virus envelope glycoproteins. Virology 248: 357-371;						
	95	Jacobson, J. et al. (1999) Results of a phase I trial of single-dose PRO 542, a novel inhibitor of HIV entry. Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy 14;						
	96	Ji, H. et al. (1999) Inhibition of human immunodeficiency virus type 1 infectivity by the gp41 core: role of a conserved hydrophobic cavity in membrane fusion. J. Virol. 73: 8578-8586;						
	97	Jiang, S. et al. (1993) HIV-1 inhibition by a peptide. Nature 365: 113;						
	98	Kilby, J.M. et al. (1998) Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry, Nature Med. 4: 1302-1307;						
	99	Kwong, P.D. et al. (1998) Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393: 648-659;						
	100	Laal, S. et al. (1994) Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies. J. Virol. 68: 4001-4008;						
	101	LaCasse, R.A. et al. (1999) Fusion-competent vaccines: broad neutralization of primary isolates of HIV. Science 283: 357-362;						
EXAMINER 				DATE CONSIDERED 01/22/05				
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

§ Note that this column shows Exhibit numbers, not reference numbers. Reference numbers are listed on pages 14-31 of the attached Amendment.



PTO-1449

**U.S. Department of Commerce
Patent and Trademark Office**

Atty. Docket No.
62942-B/JPW/AJD

Serial No.
09/912,824



Applicant(s)
Graham P. Allaway et al.

Filing Date
July 25, 2001

Group Art Unit
1648

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

Examiner Initials	Exh. No. [§]	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	32	2 0 0 3 / 0 0 2 3 0 4 4	01/30/03	Li et al.			
	33	2 0 0 2 / 0 0 4 8 7 8 6	04/25/02	Rosen et al.			
	34	2 0 0 2 / 0 0 6 1 8 3 4	05/23/02	Rosen et al.			
	35	2 0 0 2 / 0 0 7 6 7 4 5	06/20/02	Li et al.			
	36	2 0 0 2 / 0 0 9 9 1 7 6	07/25/02	Li et al.			
	37	2 0 0 2 / 0 1 0 6 7 4 2	08/08/02	Samson et al.			
	38	2 0 0 2 / 0 1 1 0 8 0 5	08/15/02	Samson et al.			
	39	2 0 0 2 / 0 1 1 0 8 7 0	08/15/02	Samson et al.			
	40	2 0 0 2 / 0 1 3 2 2 6 9	09/19/02	Li et al.			
		41	Pending claims in 10/681,879				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

102	Lehner, T. et al. (2001) Immunogenicity of the extracellular domains of C-C chemokine receptor 5 and the in vitro effects on simian immunodeficiency virus or HIV infectivity. J. Immunol. 166: 7446-7455;
103	Li, A. et al. (1997) Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins. AIDS Res. Hum. Retroviruses 13: 647-656;
104	Li, A. et al. (1998) Synergistic neutralization of simian-human immunodeficiency virus SHIV-vpu+ by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins. J. Virol. 72: 3235-3240;
105	Litwin, V. et al. (1996) Human immunodeficiency virus type 1 membrane fusion mediated by a laboratory-adapted strain and a primary isolate analyzed by resonance energy transfer. J. Virol. 70: 6437-6441;
106	Mack, M. et al. (1998) Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanisms of HIV infectivity. J. Med. 187: 1215-1224;

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[§] Note that this column shows Exhibit numbers, not reference numbers. Reference numbers are listed on pages 14-31 of the attached Amendment.

Patent and Trademark Office		Applicant(s) Graham P. Allaway et al.	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		Filing Date July 25, 2001	Group Art Unit 1648
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	107	Markosyan, R.M. et al. (2002) The mechanism of inhibition of HIV-1 Env-mediated cell-cell fusion by recombinant cores of gp41 ectodomain. <i>Virology</i> 302: 174-184;	
	108	McKnight, A. et al. (1997) Inhibition of human immunodeficiency virus fusion by a monoclonal antibody to a co-receptor (CXCR3) is both cell type and virus strain dependent. <i>J. Virol.</i> 71: 1692-1696;	
	109	Mohan, P. et al. (1992) Sulfonic acid polymers as a new class of human immunodeficiency virus inhibitors. <i>Antiviral Res.</i> 18: 139-150;	
	110	Nagashima, K.A. et al. (2001) Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potentially synergistic in blocking virus-cell and cell-cell fusion. <i>J. Infect. Dis.</i> 183: 1121-1125;	
	111	Olson, W.C. et al. (1999) Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. <i>J. Virol.</i> 73: 4145-4155;	
	112	Parren, P.W. et al. (2001) Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. <i>J. Virol.</i> 75: 8340-8347;	
	113	Posner, M.R. et al. (1993) Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120. <i>J. Acq. Immune Defic. Synd.</i> 6: 7-14;	
	114	Rudikoff, et al. (1982) Single amino acid substitution altering antigen-binding specificity. <i>Proc. Natl. Acad. Sci. U.S.A.</i> 79: 1979-1983;	
	115	Schols, D. et al. (1990) Dextran sulfate and other polyanionic anti-HIV compounds specifically interact with the viral gp120 glycoprotein expressed by T-cells persistently infected with HIV-1. <i>Virology</i> 175: 556-561;	
	116	Schols, D. et al. (1991) Selective inhibitory activity of polyhydroxycarboxylates derived from phenolic compounds against human immunodeficiency virus replication. <i>J. Acq. Immune Defic. Synd.</i> 4: 677-685;	
	117	Strizki, J.M. et al. (1997) A monoclonal antibody (12G5) directed against CXCR4 inhibits infection with the dual-tropic human immunodeficiency virus type 1 isolate HIV-1 89.6 but not the T-tropic isolate HIV-1 HxB J. <i>Virol.</i> 71: 5678-5683;	
	118	Thali, M. et al. (1992) Cooperativity of neutralizing antibodies directed against the V3 and CD4 binding regions of the human immunodeficiency virus gp120 envelope glycoprotein. <i>J. Acq. Immune Defic. Synd.</i> 5: 591-599;	
	119	Tilley, S.A. et al. (1992) Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4-binding site of gp120. <i>AIDS Res. Hum. Retroviruses</i> 8: 461-467;	
	120	Tilley, S. A. et al. (1991) Potent neutralization of HIV-1 by human and chimpanzee monoclonal antibodies directed against three distinct epitope clusters of gp120. <i>Sixieme Colloque Des Cent Gardes.</i> pp. 211-216	
EXAMINER		DATE CONSIDERED	
		01/22/05	
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

[§] Note that this column shows Exhibit numbers, not reference numbers. Reference numbers are listed on pages 14-31 of the attached Amendment.

Patent and Trademark Office INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		Applicant(s) Graham P. Allaway et al.	
		Filing Date July 25, 2001	Group Art Unit 1648
		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	121	Trkola, A. et al. (1996) CD4-dependent, antibody sensitive interactions between HIV-1 and its co-receptor CCR-5. <i>Nature</i> 384: 184-187;	
	122	Trkola, A. et al. (2001) Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. <i>J. Virol.</i> 75: 579-588;	
	123	Trkola, A. et al. (1998) Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage. <i>J. Virol.</i> 72: 1876-1885;	
	124	Vijh-Warrier, S. et al. (1996) Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4- binding site. <i>J. Virol.</i> 70:4466-4473;	
	125	Vita, C. et al. (1999) Rational engineering of a miniprotein that reproduces the core of the CD4 site interacting with HIV-1 envelope glycoprotein. <i>Proc. Natl. Acad. Sci. U.S.A.</i> 96: 13091-13096;	
	126	Wild, C. et al. (1993) A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. <i>AIDS Res. Hum. Retroviruses</i> 9: 1051-1053;	
	127	Wild, C. et al. (1995) The inhibitory activity of an HIV type 1 peptide correlates with its ability to interact with a leucine zipper structure. <i>AIDS Res. Hum. Retroviruses</i> 11: 323-325;	
	128	Wild, C. et al. (1992) A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. <i>Proc. Natl. Acad. Sci. U.S.A.</i> 89: 10537-10541;	
	129	Wild, C. et al. (1994) Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. <i>Proc. Natl. Acad. Sci. U.S.A.</i> 91: 9770-9774;	
	130	Wu, L. et al. (1997) Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. <i>J. Exp. Med.</i> 186: 1373-1381;	
	131	Wu, L. et al. (1997) CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, <i>in vitro</i> . <i>J. Exp. Med.</i> 185: 1681-1691; and	
	132	Ylisastigui, L. et al. (1998) Synthetic full length and truncated RANTES inhibit HIV-1 infection of primary macrophages. <i>AIDS</i> 12: 977-984.	
EXAMINER		DATE CONSIDERED	
		01/22/05	
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

[§] Note that this column shows Exhibit numbers, not reference numbers. Reference numbers are listed on pages 14-31 of the attached Amendment.